Circulating Levels of PD-L1, TIM-3 and MMP-7 Are Promising Biomarkers to Differentiate COVID-19 Patients That Require Invasive Mechanical Ventilation
Overview
Molecular Biology
Authors
Affiliations
Background: COVID-19 is an infectious disease caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Many COVID-19 patients require invasive mechanical ventilation (IMV) while others, even with acute respiratory failure, do not (NIMV). Therefore, we aimed to evaluate serum levels of MMP-7 and molecules related to exhausted T-cells as potential biomarkers to differentiate between IMV and NIMV patients. Methods: 105 patients diagnosed with COVID-19 and confirmed by RT-PCR for SARS-CoV-2 were divided into two groups according to the requirement for IMV. Serum levels of sPD-L1, sPD-L2, sTIM-3, sGal-9 and sMMP-7 were quantified by ELISA and correlated with clinical data. Twelve patients were followed up after eight months to compare the levels of the biomarkers between acute disease and post-COVID-19. Results: IMV patients experienced a lower PaO2/FiO2 (p < 0.0001) and a longer hospital stay (p < 0.0001), and exhibited higher levels of sPD-L1 (p < 0.05), sTIM-3 (p < 0.01) and sMMP-7 (p < 0.0001) when compared with NIMV patients. According to a ROC analysis, sMMP-7 had the highest sensitivity (78%) and specificity (76%) with a cut point of 4.5 ng/mL, followed by sTIM-3 and sPD-L1. Eight months post-COVID-19, IMV patients displayed a significant decrease in the initially high levels of sPD-L1, sTIM-3 and sGal-9, while sPD-L2 was increased, and sMMP-7 was unchanged. Conclusion: Circulating levels of sPD-L1, sTIM-3 and sMMP-7 are potential biomarkers of disease severity to distinguish patients requiring IMV. MMP-7 could also be a marker for the persistence of lung lesions post-COVID-19.
Proteomic Analyses in COVID-19-Associated Secondary Hemophagocytic Lymphohistiocytosis.
Canny S, Stanaway I, Holton S, Mitchem M, ORourke A, Pribitzer S Crit Care Explor. 2025; 7(2):e1203.
PMID: 39888602 PMC: 11789895. DOI: 10.1097/CCE.0000000000001203.
Utility of Protein Markers in COVID-19 Patients.
Alicia L, Maria Angeles O, Desiree M, Maximino R, Marilina G Int J Mol Sci. 2025; 26(2).
PMID: 39859366 PMC: 11766239. DOI: 10.3390/ijms26020653.
Eldien H, Almaeen A, El Fath A, Taha A, Ahmed R, Elfadil H Diagnostics (Basel). 2025; 15(2).
PMID: 39857114 PMC: 11763845. DOI: 10.3390/diagnostics15020229.
TIM3 in COVID-19; A potential hallmark?.
Zamani M, Sacha P Heliyon. 2025; 10(23):e40386.
PMID: 39759854 PMC: 11700678. DOI: 10.1016/j.heliyon.2024.e40386.
Precision disease management: prognostic biomarker for chronic lung damage in long COVID.
Oo A, Chu J ERJ Open Res. 2024; 10(6).
PMID: 39624388 PMC: 11610080. DOI: 10.1183/23120541.00647-2024.